drugset / Trial / NCT00078819

Etanercept (Enbrel®) in Psoriasis - Pediatrics

NCT00078819

Phase 3 Completed 211 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and efficacy of etanercept (Enbrel®) in children with Psoriasis.

Timeline

Start
2004-09-08
Primary completion
2006-02-01
Completion
2007-06-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 0.8 mg/kg Subcutaneous

Indications